Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant
Status:
Terminated
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well giving bortezomib, lenalidomide, and dexamethasone
together works in treating patients with multiple myeloma undergoing stem cell transplant.
Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in
different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as
dexamethasone, work in different ways to stop the growth of cancer cells, either by killing
the cells or by stopping them from dividing. Giving bortezomib, lenalidomide, and
dexamethasone together may kill more cancer cells.